Sun Yiqing, Zhu Bukun, Li Xiang, Luo Zhanyang, Bian Weiguo
Department of Orthopedics, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.
Department of Infection, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Front Public Health. 2025 May 2;13:1560973. doi: 10.3389/fpubh.2025.1560973. eCollection 2025.
Hepatitis B virus (HBV) is a major cause of chronic liver disease. While the hepatitis B vaccine has been proven effective in preventing HBV infection, concerns regarding Events Supposedly Attributable to Vaccination or Immunization (ESAVI) persist. This study aims to utilize the Vaccine Adverse Event Reporting System (VAERS) database to explore potential associations between the hepatitis B vaccine and musculoskeletal system AEs, providing a scientific basis for vaccine safety evaluations.
This study analyzed VAERS data from 1990 to 2024, focusing on 76,887 reports associated with hepatitis B vaccines. Disproportionality analysis methods, such as the Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR), were applied to identify the distribution and signal strength of musculoskeletal-related AEs. Furthermore, multivariable logistic regression analysis was conducted to explore association between patients with HBV vaccine and death.
Musculoskeletal system ESAVIs constituted a significant portion of all reports, including tendon fibrosis (ROR = 251.82), myofascitis (ROR = 107.51), fasciitis (ROR = 71.52), and osteoarthritis (ROR = 7.56). Tendon fibrosis demonstrated the strongest association, potentially linked to chronic inflammatory responses and abnormal tissue repair induced by aluminum adjuvants. Most AEs occurred within 30 days post-vaccination, though some, such as myofascitis, had a longer mean onset time (1,671 days), reflecting the slow-release properties of aluminum adjuvants. In multivariable logistic regression analysis, we concluded that male and combination vaccine treatment were risk factors while age from18-64 years was a protective factors of death.
This study identifies potential associations between hepatitis B vaccination and musculoskeletal system AEs, emphasizing the need for thorough pre-vaccination assessments and post-vaccination monitoring for high-risk individuals.
乙型肝炎病毒(HBV)是慢性肝病的主要病因。虽然乙肝疫苗已被证明能有效预防HBV感染,但对疑似疫苗接种或免疫相关事件(ESAVI)的担忧依然存在。本研究旨在利用疫苗不良事件报告系统(VAERS)数据库,探索乙肝疫苗与肌肉骨骼系统不良事件之间的潜在关联,为疫苗安全性评估提供科学依据。
本研究分析了1990年至2024年的VAERS数据,重点关注76,887份与乙肝疫苗相关的报告。采用比例报告率(PRR)和报告比值比(ROR)等不成比例分析方法,以确定肌肉骨骼相关不良事件的分布和信号强度。此外,进行多变量逻辑回归分析,以探讨接种乙肝疫苗患者与死亡之间的关联。
肌肉骨骼系统ESAVI在所有报告中占很大比例,包括肌腱纤维化(ROR = 251.82)、肌筋膜炎(ROR = 107.51)、筋膜炎(ROR = 71.52)和骨关节炎(ROR = 7.56)。肌腱纤维化显示出最强的关联,可能与铝佐剂诱导的慢性炎症反应和异常组织修复有关。大多数不良事件发生在接种疫苗后的30天内,不过有些事件,如肌筋膜炎,平均发病时间较长(1671天),这反映了铝佐剂的缓释特性。在多变量逻辑回归分析中,我们得出结论,男性和联合疫苗治疗是死亡的危险因素,而18至64岁的年龄是死亡的保护因素。
本研究确定了乙肝疫苗接种与肌肉骨骼系统不良事件之间的潜在关联,强调了对高危个体进行全面的接种前评估和接种后监测的必要性。